C21 · Pharmaceuticals · Global
Phase 3 KRAS and RAS inhibitor trials
Global: 36 in as of 27 Sep 2026.
- 36 Latest · Global · as of 27 Sep 2026
- Irregular Release cadence
- 1 Record · 1 region · 2026
Verified 27 Sep 2026 · 1 publisher
The figure
One published observation so far. A chart follows as soon as a second period is published.
Phase 3 KRAS and RAS inhibitor trials
Global, as of 27 Sep 2026
Every record
1 record · 1 region · 2026. Each period links to its record: the value, its source evidence and original document.
| Period | Value | Source | Type |
|---|---|---|---|
| Global 1 record | |||
| as of 27 Sep 2026 | 36 | ClinicalTrials.gov · 27 Sep 2026 | |
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: ClinicalTrials.gov. Licence: CC BY 4.0.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (ClinicalTrials.gov); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Count of interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) registered as Phase 3 or Phase 2/3, any start date.
- Measure
- One slice of Clinical trial registrations ( basis: clinicaltrials gov registry, counting rule: phase 3, form: count, segment: kras ) . Total number of clinical trials registered with a clinical trials registry platform. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 1 document
Other slices of clinical trial registrations
- Clinical trial registrations 3
- New drug clinical trials 2 new drug
- Active Alzheimer's disease drug trials 1 clinicaltrials gov registry · currently active · alz
- Active GLP-1, incretin multi-agonist and amylin trials 1 clinicaltrials gov registry · currently active · glp1
- Active KRAS and RAS inhibitor trials 1 clinicaltrials gov registry · currently active · kras
- Active antibody-drug conjugate trials 1 clinicaltrials gov registry · currently active · adc
- Active autoimmune cell therapy and T-cell engager trials 1 clinicaltrials gov registry · currently active · autoimmune
- Active cardiometabolic RNA and next-generation lipid drug trials 1 clinicaltrials gov registry · currently active · rnacv
- Active gene editing trials 1 clinicaltrials gov registry · currently active · gene
- Active inflammatory bowel disease drug trials 1 clinicaltrials gov registry · currently active · ibd
- Active oncology bispecific antibody trials 1 clinicaltrials gov registry · currently active · bsab
- Active radioligand therapy trials 1 clinicaltrials gov registry · currently active · rlt
Frequently asked questions
What is the latest phase 3 KRAS and RAS inhibitor trials?
Global: 36 in as of 27 Sep 2026.
Where does this data come from?
From 1 document published by ClinicalTrials.gov. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Irregularly: the publishers behind this measure do not release it on a fixed schedule. A new figure appears here once it is published and verified.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Phase 3 KRAS and RAS inhibitor trials [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/ctgov-kras-phase-3-trials
"Phase 3 KRAS and RAS inhibitor trials." StatOrigin, 2026, https://statorigin.org/indicators/ctgov-kras-phase-3-trials. Accessed 28 Oct. 2026.
StatOrigin. "Phase 3 KRAS and RAS inhibitor trials." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/ctgov-kras-phase-3-trials.
@misc{statorigin_ctgov_kras_phase_3_trials_2026, title = {Phase 3 KRAS and RAS inhibitor trials}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/ctgov-kras-phase-3-trials}, note = {Data set. Accessed 2026-10-28} }